Michael J. Morris, MD

Articles

Dr. Morris on Next Steps for PSMA–Targeted PET Imaging in Prostate Cancer

July 30th 2020

Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer

July 9th 2020

Michael J. Morris, MD, discusses the ​design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Dr. Morris on Deciding Among PET Tracers in Prostate Cancer

June 19th 2020

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

Dr. Morris on the Promise of PSMA-Targeted PET Imaging in Prostate Cancer

June 15th 2020

Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Dr. Morris on Impact of PSMA-Targeted Imaging on Clinical Management of Prostate Cancer

June 5th 2020

Michael J. Morris, MD, discusses the impact of prostate-specific membrane antigen-targeted imaging with 18F-DCFPyL-PET/CT on the clinical management of patients with prostate cancer.

Dr. Morris Discusses Biomarkers in Prostate Cancer

December 17th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses biomarkers in prostate cancer.

Dr. Morris Discusses PSMA-Targeted Imaging in mCRPC

November 20th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.

Dr. Morris on the Next Steps With Bone Biomarkers for Prostate Cancer

May 11th 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the next steps regarding bone biomarkers for patients with prostate cancer.

Dr. Morris on Challenges of Radium-223 Treatment in Prostate Cancer

February 23rd 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with radium-223 treatment in prostate cancer.

Dr. Morris on Bone Biomarkers for Radium-223 in Prostate Cancer

February 18th 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

x